Rocket Lab’s $44 Billion Paradox: Record Orders, a Crashing Share Price, and the Neutron Clock
Published on 07/28/2026 at 14:32 | Redaktion boerse-global.de
The numbers don’t lie — but they tell two completely different stories. Rocket Lab’s order book has swelled to a record €2.2 billion, the company just locked in a €266 million hypersonics contract with the U.S. Space Force, and first-quarter revenue surged more than 60% year over year. Yet the stock has shed 33.5% in the past 30 days alone, sliding to €57.20 and sitting 57.3% below its May peak of €133.80. That gap between operational momentum and market sentiment has rarely been this wide — or this instructive.
The Iridium Bill Comes Due
The catalyst for the sell-off isn’t hard to find. On June 29, Rocket Lab announced it would acquire Iridium Communications for $8 billion, swallowing a fully operational L-band satellite constellation in one gulp. Strategically, the move makes sense: it buys the company a decade of infrastructure build-out overnight and positions it as a vertically integrated space and defense platform. But the price tag is punishing. The deal is backed by a $3.6 billion bridge loan, and existing shareholders face a tangible dilution risk. For a company that was already burning cash to fund its next-generation rocket, the balance sheet suddenly looks a lot more leveraged.
The market is now pricing that financing risk rather than the underlying business model. The transaction isn’t expected to close until mid-2027, leaving a long tunnel of uncertainty. Investors who were willing to bet on the Neutron rocket story a few months ago are now staring at a heavily indebted acquirer — and they’re voting with their feet.
Neutron: The Make-or-Break Variable
The Iridium deal isn’t the only source of anxiety. Rocket Lab’s medium-lift, reusable Neutron rocket was originally slated for its maiden flight this month. In February, the company pushed that timeline to late 2026 — a delay that rippled through a customer base that includes the U.S. Air Force, NASA, and an unnamed satellite operator, all of whom had been expecting regular launches in a reasonable timeframe.
Should investors sell immediately? Or is it worth buying Rocket Lab?
There has been genuine technical progress. This month, Rocket Lab completed a full hot-fire test of the Archimedes vacuum engine, a critical milestone. But the competitive window is narrowing. Firefly Aerospace, in partnership with Northrop Grumman, is developing its own medium-class rocket called Eclipse, which could reach orbit as soon as next year. If a rival vehicle gets there first, some potential Neutron customers may not wait around.
Defense Dollars Are Real — But So Is the Dilution
The recent flurry of government contracts isn’t window dressing. The U.S. Space Force deal for HASTE suborbital missions from Alaska is part of a broader shift: space systems and defense infrastructure now account for roughly three-quarters of Rocket Lab’s total backlog. The company is transforming from a small-launch specialist into a defense and infrastructure supplier, and the revenue trajectory supports that narrative.
But here’s the rub: that operational strength is running parallel to a business that continues to burn cash and issue new shares to fund growth. The relative strength index sits at 33.4, deep in oversold territory, yet the stock keeps sliding. The disconnect between fundamentals and price action is widening by the week, not narrowing.
Wall Street’s Split Screen
The analyst community is deeply divided. Piper Sandler recently initiated coverage with a neutral rating and an $83 price target, explicitly citing the stock’s elevated valuation relative to peers. Other houses have upgraded the stock on the back of the recent defense wins. The consensus target sits at €100.51, implying roughly 76% upside from current levels. That kind of spread between bulls and bears isn’t just disagreement about the narrative — it’s the market struggling to price execution risk.
Rocket Lab at a turning point? This analysis reveals what investors need to know now.
Rocket Lab’s market capitalization stands at €44.36 billion. For a company that has yet to post positive earnings, with a delayed rocket program and a multibillion-dollar acquisition still in limbo, that valuation demands a lot of future perfection. The stock has also bounced 77% from its November low, a reminder of just how speculative the sentiment around this name has become.
The Second-Half Pivot
The remainder of 2026 hinges on a single event: the maiden flight of Neutron, scheduled for the fourth quarter. If CEO Peter Beck can deliver that launch and begin integrating Iridium without derailing the core business, the current discount to the May high could look like a massive mispricing in hindsight. But until Neutron is actually on the launch pad and the Iridium integration shows tangible progress, the stock remains what it is today — a high-volatility prisoner of its own ambition, caught between record orders and a market that has run out of patience.
Ad
Rocket Lab Stock: New Analysis - 28 July
Fresh Rocket Lab information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
